Cytokinetics IncCYTK
What Cytokinetics Inc does.
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial product is MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, and 20 mg tablets, which the FDA approved in December 2025. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. The approval of MYQORZO included a risk evaluation and mitigation strategy (REMS) program to ensure the benefits of the drug outweigh the risk of heart failure due to systolic dysfunction. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract obstruction. MYQORZO became available for prescription to patients on or around January 27, 2026. In addition, in February 2026, the European Commission approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) oHCM in adult patients. Moreover, in December 2025, the China National Medical Products Administration approved MYQORZO for the treatment of adults with (New York Heart Association class II-III) oHCM, to improve exercise capacity and symptoms.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Net income | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Free cash flow | -$2.1M | -$191.4M | -$310.9M | -$415.7M | -$399.8M | -$534.8M |
More on CYTK.
- Cytokinetics Inc summary
- Cytokinetics Inc financial statements
- Cytokinetics Inc key metrics
- Cytokinetics Inc health scores and style box
- Cytokinetics Inc earnings
- Cytokinetics Inc dividends
- Cytokinetics Inc valuation
- Cytokinetics Inc ownership and insiders
- Cytokinetics Inc peers
Figures from Cytokinetics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.